article thumbnail

Beyond Covid-19: the disruptive potential of RNA-based therapeutics

Pharmaceutical Technology

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

article thumbnail

Two new drugs added to WHO list of COVID-19 therapies

pharmaphorum

The drug, developed by Incyte and licenced to Lilly, is also used to treat rheumatoid arthritis. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. .

Hospitals 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

USP standards build trust in biologics and biosimilars

Quality Matters

Novel biologics and biosimilars – or biologics highly similar to an existing biologic already approved – also hold great promise to help increase availability of quality biologic medicines for conditions ranging from diabetes to cancer. Another example is mRNA vaccines. The modality is the same regardless of the disease target.

article thumbnail

ACE-1334 by Merck for Lung Disease: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

BI-685509 by Boehringer Ingelheim International for Systemic Sclerosis (Scleroderma): Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Edoxaban tosylate by Daiichi Sankyo for Atrial Fibrillation: Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

Waters, as a strategic partner to the pharma industry, can help India become a world leader in biosimilars

Express Pharma

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?